Biomerica Inc. Common Stock (BMRA)
Stock · NASDAQ · Health Care
$1.85as of 10/16/2026
Price chart
Active signals
BMRA Signal Track Record
How signals performed across all stocks →What BMRA's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 26 | -1.5% | 38% | June 18, 2026 |
| Bollinger Band Breakout | 19 | -5.9% | 37% | September 22, 2026 |
| Bollinger Band Breakdown | 16 | -6.5% | 38% | October 7, 2026 |
| 200-Day Moving Average TouchActive now | 9 | -13.2% | 22% | October 2, 2026 |
| Any 20-session window (baseline) | -5.7% | 37% |
Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About BMRA
Biomerica, Inc., a biomedical technology company, engages in developing, patenting, manufacturing, and marketing of diagnostic and therapeutic products for the detection and treatment of medical conditions and diseases in North America, Asia, Europe, the Middle East, and South America. The company offers diagnostic test kits are used to analyze blood, urine, nasal, or fecal material from patients to aid in the diagno…
- Sector
- Health Care
- Industry
- Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Employees
- 50
- Website
- biomerica.com/
Fundamentals
- 1-day range
- $1.81$1.95
- Market cap
- $4.94M
- P/E (trailing)
- —
- P/E (forward)
- 4.95
- EPS (trailing)
- $-1.26
- Dividend yield
- —
- Beta
- 0.41
- Avg. volume
- 71.3K
How Biomerica Inc. Common Stock Makes Money
Where the revenue actually goes — FY2026 annual results
Source: 10-K filed Aug 31, 2026 · via SEC EDGAR / Finnhub
Biomerica Inc. Common Stock Competitors
Chosen by industry and closest market cap.
- BMRABiomerica Inc. Common Stock$1.85▼ 1.60%Market cap $4.94MP/E —$1.45$3.21
- CDIOCardio Diagnostics Holdings Inc. Common stock$1.69▼ 3.98%Market cap $4.91MP/E —$0.97$7.91
- VRAXVirax Biolabs Group Limited Ordinary Shares$1.45▼ 10.49%Market cap $2.21MP/E —$1.55$21.75
- TRIBTrinity Biotech plc American Depositary Shares$8.03▲ 1.26%Market cap $7.86MP/E —$5.01$52.5
- VNRXVolitionRX Limited Common Stock$0.18▼ 5.26%Market cap $9.23MP/E —$0.18$10.31
- CDIOWCardio Diagnostics Holdings Inc. Warrant$0.0064▼ 28.09%Market cap $50.3KP/E —$0.0052$0.0721
- QCLSQ/C Technologies Inc. Common Stock$0.538▼ 3.58%Market cap $21.99MP/E —$0.4201$8.17
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| BMRA Biomerica Inc. Common Stock | $4.94M | — | $1.85 | ▼ 1.60% | $1.45$3.21 |
| CDIO Cardio Diagnostics Holdings Inc. Common stock | $4.91M | — | $1.69 | ▼ 3.98% | $0.97$7.91 |
| VRAX Virax Biolabs Group Limited Ordinary Shares | $2.21M | — | $1.45 | ▼ 10.49% | $1.55$21.75 |
| TRIB Trinity Biotech plc American Depositary Shares | $7.86M | — | $8.03 | ▲ 1.26% | $5.01$52.5 |
| VNRX VolitionRX Limited Common Stock | $9.23M | — | $0.18 | ▼ 5.26% | $0.18$10.31 |
| CDIOW Cardio Diagnostics Holdings Inc. Warrant | $50.3K | — | $0.0064 | ▼ 28.09% | $0.0052$0.0721 |
| QCLS Q/C Technologies Inc. Common Stock | $21.99M | — | $0.538 | ▼ 3.58% | $0.4201$8.17 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
Insider Activity
Insider Actions →- Chin Eric · August 26, 2026 · Buy6.3K @ $1.6
- MOATAZEDI DAVID · August 26, 2026 · Buy10.0K @ $1.6
- Irani Zackary S. · August 26, 2026 · Buy31.3K @ $1.6
- BARBIERI ALLEN · August 26, 2026 · Buy20.0K @ $1.6
- Gary M. Huff · August 20, 2026 · Buy31.3K @ $1.6
Institutional Ownership
March 31, 2026
- Total shares held
- 101.5K
- Total value held
- $214.5K
- Institutional holders
- 9
- Unknown56.0K
- Unknown18.6K
- Unknown14.5K
- Unknown10.8K
- Unknown825
- Unknown519
- Unknown125
- Unknown6
- Unknown1
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 16, 2026
Biomerica reports Q1 earnings with lower EPS and sales
Biomerica released its first‑quarter results, showing earnings per share of $0.37 and revenue of $1.265 million, both lower than the prior year’s $1.38 million sales figure. The decline in sales highlights a contraction in top‑line performance for the quarter. The company’s shares are currently near the lower end of its 52‑week range, which may provide context for market participants.
Biomerica reports Q1 earnings with lower EPS and sales. Biomerica released its first‑quarter results, showing earnings per share of $0.37 and revenue of $1.265 million, both lower than the prior year’s $1.38 million sales figure. The decline in sales highlights a contraction in top‑line performance for the quarter. The company’s shares are currently near the lower end of its 52‑week range, which may provide context for market participants.